I don't see it as a particularly positive report for the Life Sciences division, some good news from energy though.
- First acknowledgement from the company that we missed the boat on COVID RATs by essentially pulling out of markets. While those markets are some of the more price sensitive, all markets are price sensitive if you are not offering a ***valued*** point of difference from the cheaper competition. I'm not convinced we are.
- COVID/Flu A/Flu B test - it's good that this is progressing but I can't help but feel this may pass us by too. (In my non-expert opinion) as COVID becomes more and more like the Flu it is less critical to be able to diagnose between them - isolate and rest for both. This is different to when COVID was considerably worse than the Flu. Leads back to point 1, will this be a ***valued*** point of difference - at least it would open up more opportunities in the US - ironically the one jurisdiction we aren't seeking approvals in.
- Sepsis comments are a bit strange. I likely skew more negative than most (and readily admit not to wear rose coloured glasses) but I worry that they are preparing us for "we have a great test but the market is too complex and fragmented for entry in the near future". The planned evaluation is obviously a good thing, the way they have communicated it makes it sound like a potential roadblock as opposed to an optimisation of a committed path. They do say "AnteoTech remains committed to developing biomarkers to aid in the diagnosis of Sepsis" which is good to hear and likely means I am wrong. To me the evaluation of the market and regulatory requirements sounds like such a fundamental step in launching a medical diagnostic product that it would just be something done as part of development of a new test. Perhaps this is the refreshed Boards way of communicating to shareholders just how bad it was when they took over.
- Forums
- ASX - By Stock
- ADO
- Ann: Quarterly Update and Appendix 4C
Ann: Quarterly Update and Appendix 4C, page-46
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ADO (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.6¢ |
Change
-0.003(10.3%) |
Mkt cap ! $64.73M |
Open | High | Low | Value | Volume |
3.0¢ | 3.0¢ | 2.6¢ | $209.8K | 7.543M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 592714 | 2.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.8¢ | 269442 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 592714 | 0.026 |
8 | 1513341 | 0.025 |
9 | 1391573 | 0.024 |
3 | 1165217 | 0.023 |
5 | 316454 | 0.022 |
Price($) | Vol. | No. |
---|---|---|
0.028 | 269442 | 1 |
0.029 | 130000 | 1 |
0.030 | 32000 | 1 |
0.031 | 100000 | 1 |
0.032 | 450000 | 3 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
ADO (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online